White matter of perinatally HIV infected older youths shows low frequency fluctuations that may reflect glial cycling

Manoj K. Sarma1, Amrita Pal2, Margaret A. Keller3,4, Tamara Welikson5, Joseph Ventura5, David E. Michalik6, Karin Nielsen-Saines7, Jaime Deville7, Andrea Kovacs8,9, Eva Okerskalski8,9, Joseph A. Church10, Paul M. Macey2, Bharat Biswal11 & M. Albert Thomas1

In perinatally HIV-infected (PHIV) children, neurodevelopment occurs in the presence of HIV-infection, and even with combination antiretroviral therapy (cART) the brain can be a reservoir for latent HIV. Consequently, patients often demonstrate long-term cognitive deficits and developmental delay, which may be reflected in altered functional brain activity. Our objective was to examine brain function in PHIV on cART by quantifying the amplitude of low frequency fluctuations (ALFF) and regional homogeneity (ReHo). Further, we studied ALFF and ReHo changes with neuropsychological performance and measures of immune health including CD4 count and viral loads in the HIV-infected youths. We found higher ALFF and ReHo in cerebral white matter in the medial orbital lobe for PHIV (N = 11, age mean ± sd = 22.5 ± 2.9 years) compared to controls (N = 16, age = 22.5 ± 3.0 years), with age and gender as co-variates. Bilateral cerebral white matter showed increased spontaneous regional activity in PHIV compared to healthy controls. No brain regions showed lower ALFF or ReHo in PHIV compared to controls. Higher log10 viral load was associated with higher ALFF and ReHo in PHIV in bilateral cerebral white matter and right cerebral white matter respectively after masking the outcomes intrinsic to the brain regions that showed significantly higher ALFF and ReHo in the PHIV compared to the control. Reductions in social cognition and abstract thinking in PHIV were correlated with higher ALFF at the left cerebral white matter in the left medial orbital gyrus and higher ReHo at the right cerebral white matter in the PHIV patients. Although neuroinflammation and associated neuro repair were not directly measured, the findings support their potential role in PHIV impacting neurodevelopment and cognition.

Although there is still no definitive cure for human immunodeficiency virus (HIV), the tremendous success of combination antiretroviral therapy (cART) has transformed both perinatal HIV (PHIV) and HIV into a treatable chronic disease1–5. However, it has been observed that poor penetration of some antiretrovirals across the blood–brain barrier may provide insufficient protection of the central nervous system (CNS)6–8. This has led to serious concerns regarding the brain's role as a sanctuary site for HIV. It has been reported that long-term cART treatment may be associated with potential mitochondrial toxicity, metabolic abnormalities, impaired neurogenesis and may cause neuronal loss9–11. Furthermore, the many children who have survived to adulthood from earlier eras with less efficacious regimens may experience indolent ongoing brain injury. Consequently,
although increasing numbers of children born with HIV infection are surviving into adulthood, they remain at risk for long-term central nervous system damage.

Neurodevelopment takes place in HIV youths in the presence of HIV-infection as PHIV patients acquired the infection at birth and in utero. On the other hand, in adult-acquired HIV infection, neuro-development may more likely have happened prior to infection. As a result, brain related effects of chronic HIV-infection may vary in PHIV individuals compared to other HIV-infected patients. Developmental delay and behavioral problems have been reported from neuropsychological studies of PHIV-infected children receiving ART. In addition, deficiency in neurocognitive functions including psychomotor ability, language, executive function, visual–spatial, and memory has been reported compared to uninfected healthy controls. Our recent study on perinatally HIV-infected older youths receiving ART showed a decrease in attention/processing speed in HIV-infected youths relative to HIV-negative controls, indicating that cognitive abnormalities persist as these children reach adolescence and adulthood. Brain abnormalities likely underlie these cognitive and other developmental difficulties in HIV-infected youths.

Previous neuroimaging findings in perinatally HIV-infected children on ART include ventricular enlargement and/or sulcal widening, calcification of the basal ganglia and corpus callosum, white matter signal abnormalities and lesions, reduced white matter, and decreased white matter integrity. Further, some of these studies have shown that clinical, immunologic, and virologic measures were associated with volumetric measures, diffusivity markers, shape deformation, and WM alterations.

Brain function as well as structure is likely affected in HIV-infected youths. Brain function can be studied with resting-state functional magnetic resonance imaging (rs-fMRI). Resting fMRI measures the spontaneous blood oxygen level-dependent (BOLD) signal, which reflects underlying neural activity, and which is used to evaluate regional interactions, and functional connectivity (FC) between brain networks. Resting fMRI avoids performance confounds of task-based imaging making it more suitable for patients with disorders of consciousness, potentially impaired clinical subjects and pediatric populations. Another advantage of rs-fMRI over task-based fMRI is the ability to identify many spatially distinct brain networks simultaneously. It has provided significant insights on brain development and has emerged as an interesting biomarker for measuring connectivity within brain networks in multiple conditions including brain tumors and psychiatric disorders such as schizophrenia. Regional homogeneity (ReHo) is one rs-fMRI metric that reflects synchrony of adjacent regions, and is considered a marker of local functional organization. Another rs-fMRI technique measures the low frequency fluctuations of the blood oxygen level dependent BOLD signal within the frequency range (0.01–0.08 Hz); this measure is termed Amplitude of Low Frequency Fluctuations (ALFF). The ALFF measure has been related to neural activity, but may reflect other phenomena as well, including astrocyte activity. The ALFF measure may therefore relate indirectly to the inflammatory state of the brain, and hence is relevant to HIV patients who likely have an ongoing high inflammatory state. The fractional ALFF (f-ALFF) analyses normalize the ALFF power by dividing by the total power in the entire detectable frequency range to represent the relative contribution of low frequency oscillations.

Although rs-fMRI has been examined in many diseases, there are limited studies on brain connectivity alterations in HIV-infected patients and their correlation with neurocognitive impairment. In adult HIV-infected patients, rs-fMRI studies reported altered FC within different brain networks, including lateral occipital cortex (LOC), salience, executive control, and default mode (DM) networks. Both lower and higher internetwork correlations, unusual functional connectivity between the dorsal caudate and the dorsolateral prefrontal cortex, and connection between HIV and measures of psychomotor speed have also been observed. On the other hand, Janssen et al. did not observe differences in subcortical connectivity between healthy controls and virologically controlled HIV-infected adult patients who were otherwise healthy. Compared to HIV-negative controls, Ortega et al. found lower cortico-striatal functional connectivity in HIV-infected patients between the striatum and the default mode network and ventral attention network. They also observed that virologically controlled HIV-infected patients showed higher connectivity between these networks than patients not virologically controlled. In HIV-associated neurocognitive disorder groups, reduced synchronicity in the salience and executive network domains despite viral suppression was reported by Chaganti et al.

To date, there are only a smaller number of rs-fMRI studies in PHIV children receiving ART. In their study on PHIV youth receiving ART, Herting et al. observed global alterations in the "default mode network" (DMN), with significant associations between disease severity and lower connectivity within the DMN. Furthermore, they found that patterns of connectivity with the posterior cingulate cortex (PCC) and medial prefrontal cortex (mPFC) varied as a function of peak HIV RNA and the rs-fMRI patterns predicted processing speed ability. Toich et al. examined the effects of HIV infection on FC in 7-year-old children who had received early ART treatment. They observed reduced long-range connectivity and increased short-range connectivity suggesting developmental delay. During infancy, they also found that poor immune health, as reflected by either lower CD4 or CD4% at enrollment, was associated with localized FC increases in the somatosensory, salience and basal ganglia networks and summarized that HIV may affect brain development from its earliest stages and persist into childhood, despite early ART. Yadav et al. evaluated the functional brain activity in HIV-infected children (mean age 9.3 years) by ALFF and FC. Compared with controls, the HIV-group showed lower ALFF in the left middle temporal gyrus, precentral and post central gyrus (principally gray matter regions), and altered FC between multiple brain regions. They also observed significantly lower NP scores in various domains, with scores correlated to ALFF and FC in HIV-infected children.

Although brain involvement with HIV is well documented for PHIV-infected infants and children, long-term neurologic outcomes for older HIV-infected youths are less understood. Herting et al. focused on the DMN connectivity in a sample with mean age of 16.5 years, Toich et al. looked at children around age 7, and Yadav et al. age 9. We aimed to study an older age group. The objective of our current study was to examine whether youth (late teens and young adults) would show altered brain function as reflected in rs-fMRI changes compared...
and sixteen healthy controls (HC) (age 22.5 ± 3.0 years, range 19.1–29.5, 9 females) participated in our study. Participants voluntarily and signed informed consent. Participants were reimbursed for their time in the study. The research protocol was approved by the institutional review board (IRB) both at Harbor-UCLA Medical Center (Departments of Pediatrics and Medicine, Torrance, CA), Miller Children’s Hospital of Long Beach (Long Beach, CA), USC Medical Center’s Maternal, Child, and Adolescent Center for Infectious Diseases and Virology, and David Geffen School of Medicine at UCLA (Los Angeles, CA). The healthy controls were recruited from the neighboring communities. The healthy controls were recruited from Harbor-UCLA Medical Center, Miller Children’s Hospital of Long Beach, USC Medical Center’s Maternal, Child, and Adolescent Center for Infectious Diseases and Virology, and David Geffen School of Medicine at UCLA (Los Angeles, CA). The healthy controls were recruited from family members of the subjects, and through fliers at UCLA, the local junior college, the Lundquist Institute and neighboring communities. The research protocol was approved by the institutional review board (IRB) both at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center and at the University of California at Los Angeles. All methods were carried out in accordance with relevant guidelines and regulations, and followed the Health Insurance Portability and Accountability Act (HIPAA). All subjects completed study procedures voluntarily and signed informed consent. Participants were reimbursed for their time in the study.

Study criteria. Study inclusion criteria were similar to our previous studies and consisted of the following: (1) 18–30 years of age; (2) perinatal acquisition of HIV or confirmation of HIV-uninfected status with Ora-Quick (OraSure Technologies, Bethlehem, PA 18015) buccal scraping (for HIV-subjects); (3) current treatment with combination antiretroviral medication for HIV-infected subjects; (4) post-menarchal status for all females since they were studied in the follicular phase of the menstrual cycle; (5) and for females negative urine pregnancy test on day of scanning. We excluded participants if they had: (1) a history of CNS opportunistic infection or other CNS condition (other than HIV); (2) severe metabolic disturbances, such as hepatic or renal failure; (3) metallic implants or braces or permanent retainers or other MRI exclusions; (4) claustrophobia; (5) Attention Deficit/Hyperactivity Disorder; (6) pregnancy (by interview and urine pregnancy test before scanning); (7) alcohol or other substance use/abuse including marijuana; (8) active psychiatric diagnosis; (9) use of chronic medications other than inhalers for asthma in control subjects; (10) severe school difficulties in control subjects; (11) female subjects pregnant or in luteal phase of menstrual cycle; (12) hepatitis C infection.

For HIV+ subjects, the following additional data were collected from chart review: age at first treatment for HIV, HIV viral load close to time of testing, highest known viral load, CD4 T cell count close to time of testing, lowest known CD4, lowest known CD4%, current antiretroviral therapy, known presence of HIV encephalopathy, and history of maternal substance abuse during pregnancy. The clinical variables are summarized in Table 1 and demonstrate that these patients had been treated for many years with antiretroviral therapy. Data from a life time viral load. Of the 11 PHIV participants, four had a diagnosis of HIV encephalopathy while one patient was considered to have a probable diagnosis of HIV encephalopathy. Eight of these 11 patients had experienced school difficulties. In addition, two mothers had known substance abuse during pregnancy while information for one mother was not available, and for 8 there was no evidence of substance abuse during pregnancy.

### Materials and methods

**Participants/subjects.** Eleven PHIV-infected youths (age 22.5 ± 2.9 years, range 19.6–29.1, 8 females) and sixteen healthy controls (HC) (age 22.5 ± 3.0 years, range 19.1–29.5, 9 females) participated in our study. The PHIV participants were recruited from four medical centers: Los Angeles County Harbor-UCLA Medical Center (Departments of Pediatrics and Medicine, Torrance, CA), Miller Children’s Hospital of Long Beach (Long Beach, CA), USC Medical Center’s Maternal, Child, and Adolescent Center for Infectious Diseases and Virology, and David Geffen School of Medicine at UCLA (Los Angeles, CA). The healthy controls were recruited from family members of the subjects, and through fliers at UCLA, the local junior college, the Lundquist Institute and neighboring communities. The research protocol was approved by the institutional review board (IRB) both at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center and at the University of California at Los Angeles. All methods were carried out in accordance with relevant guidelines and regulations, and followed the Health Insurance Portability and Accountability Act (HIPAA). All subjects completed study procedures voluntarily and signed informed consent. Participants were reimbursed for their time in the study.

### Table 1. Demographic and clinical characteristics. Demographic and clinical characteristics of PHIV-infected youths and healthy controls. p-value shown for group differences assessed with independent samples t-test.

| Characteristics              | PHIV-infected youth (n = 11) | Healthy controls (n = 16) | p-value |
|------------------------------|------------------------------|--------------------------|---------|
| Age (years)                  | 22.5 ± 2.9                   | 22.5 ± 3.0               | 0.96    |
| Sex (male/female)            | 3 : 8                        | 7 : 9                    | 0.40    |
| Age at ART initiation (months)| 21.64 ± 36.96 (3–129)        | –                        | –       |
| Age at HIV diagnosis (months)| 18.91 ± 36.75 (1–126)        | –                        | –       |
| Current CD4 T-cell count     | 506.73 ± 301.46 (55–963)      | –                        | –       |
| Lowest known CD4             | 268.82 ± 255.16 (37–635)     | –                        | –       |
| Lowest known CD4%            | 14 ± 10.39 (2–31)            | –                        | –       |
| Current Viral Load           | 13,124.82 ± 35,938.30 (20–11,9536) | –                  | –       |
| Highest known viral load     | 383,283.91 ± 404,037.17 (18,475–1,223,892) | –                  | –       |
| Current Log_{10} viral load  | 2.24 ± 1.40 (1–5.08)          | –                        | –       |
MRI. All MRI studies were performed using a 3 T Prisma MRI scanner (Siemens Medical Solution, Erlangen, Germany), using a 16-channel phased-array head ‘receive’ coil. During data acquisition, subjects were instructed to stare at a spot in the scanner and remain awake. To minimize head movement, foam pads were placed on either side of the head. rs-fMRI scans were collected using an echo planar imaging (EPI) sequence with: TR/TE = 2000/27 ms, Flip angle = 90°, 40 slices, matrix size = 64 × 64; FOV = 240 × 240 mm²; acquisition voxel size = 3.75 × 3.75 × 4 mm³; and 180 volumes/scan. To facilitate EPI distortion correction, a field map was acquired before the rs-fMRI scan with: TR = 430 ms, TE = 7.35/9.81 ms, matrix size = 64 × 64, FOV = 192 mm, forty 4 mm slices, no gap. In addition, a high-resolution T₁-weighted magnetization-prepared rapid gradient echo scan (MPRAGE) was acquired for anatomical information for better registration and overlay of brain activity. All the subjects were scanned at the same site.

Neurocognitive data. Patients performed a neurocognitive battery test at a separate visit from the MRI data collection. These tests were assessed in depth separately, but were included here to aid with interpretation of significant findings. All subjects were administered a comprehensive neuropsychological assessment battery by a clinical psychology trainee in the following fixed order: MATRICS Consensus Cognitive Battery (MCCB) subtests include: Brief Assessment of Cognition in Schizophrenia (BACS): Symbol Coding, Category Fluency: Animal Naming, Trail Making Test: Part A (including Part B), Continuous Performance Test—Identical Pairs (CPT-IP), Wechsler Memory Scale-3rd Ed. (WMS-III): Spatial Span, Letter-Number Span (LNS), Hopkin’s Verbal Learning Test-Revised (HVLT-R), Brief Visuospatial Memory Test-Revised (BVMT-R), Neuropsychological Assessment Battery (NAB): Mazes, Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT): Managing Emotions. Additional measures were administered as followed: Rey–Osterrieth Complex Figure Test (ROCFT) Copy, Grooved Pegboard Test, ROCFT Immediate Recall, Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), Stroop Color-Word Test (Stroop), the Positive and Negative Syndrome Scale (PANSS), Wechsler Test of Adult Reading (WTAR), and the ROCFT Delayed Recall.

The following neuropsychological measures were grouped into 12 cognitive domains for further analysis: (1) Neurocognitive Composite Score: BACS, Symbol Coding, Category Fluency: Animal Naming, Trail Making Test: Part A, CPT-IP, WMS-III, Spatial Span, LNS, HVLT-R, BVMT-R, NAB: Mazes, and MSCEIT: Managing Emotions; (2) Speed of Information Processing: BACS, Category Fluency: Animal Naming, Trail Making Test: Part A; (3) Attention/vigilance: CPT-IP; (4) Working memory: WMS-III, Spatial Span, LNS; (5) Verbal learning: HVLT-R; (6) Visual learning: BVMT-R; (7) Reasoning and problem solving: NAB: Mazes; (8) Social cognition: MSCEIT: Managing Emotions; (9) Visual Perceptual Delayed Recall: ROCFT Immediate and Delayed; (10) Psychomotor Functioning: The Groove Pegboard (dominant and non-dominant hands); (11) Executive Functioning: Trail Making Test A and B, Stroop; (12) Abstract Thinking: PANSS.

Raw data and Z-scores were transformed into T-scores by utilizing established normative data. Executive Functioning, Psychomotor Functions, and Abstract Thinking raw scores were calculated into T-scores based on the performance of controls (N = 16). Higher T-scores signified better performance across all measures.

Data processing and analysis. All images were preprocessed by SPM12 software and Matlab 2019 (Mathworks Inc., Natick, MA). The raw EPI images were realigned to the mean of the time series to correct for head motion using the standard SPM12 routine. We used the “DRIFTER” toolbox for all rs-fMRI time-series to remove local oscillatory physiologic noise like cardiac and respiratory cycles. To account for whole brain influences we performed linear detrending. fMRI images were co-registered to the anatomical scans see Methods in 7. The anatomical images were partitioned into gray matter, white matter and cerebrospinal fluid using SPM12’s “DARTEL” procedure. Each participant’s deformation map, obtained from the anatomical image, was applied to the functional images for normalization into the Montreal Neurological Institute (MNI) space with an isotropic voxel size of 2 mm³.

We used the “DPABI: Data Processing & Analysis” software package to calculate ALFF, f-ALFF and ReHo. In the software package, the time series was first converted to the frequency domain using a Fast Fourier Transform, and the averaged square root of the power spectrum for the predefined typical frequency interval 0.01–0.08 Hz was termed ALFF. We applied a bandpass filter ranging from 0.01 to 0.08 Hz to all the ALFF and f-ALFF analyses. f-ALFF measures the power within the low frequency (0.01–0.08 Hz) divided by the total power in the entire detectable frequency range to represent the relative contribution of low frequency oscillations. For ReHo we analyzed unsmoothed data as per DPABI recommendations. We bandpass-filtered the data to 0.01–0.08 Hz and the ReHo cluster was for 27 voxels, along with smoothing the ReHo outcome (sm-ReHo) images by a 6 mm full-width-at-half-maximum Gaussian kernel similar to 18. We inputted the z score signals (prefixed with z-ALFFmap, z-fALFFmap and szReHomap) outputted from DPABI, for subsequent statistical analysis with SPM12 package. Overlap in areas of difference of ALFF and ReHo indicates regions that are active at the specified frequency and are in sync with neighboring voxels, likely reflecting a large group of neurons firing together.

Once we identified the brain regions showing significantly different ALFF or ReHo values compared to controls, we conducted additional correlation analysis between the pediatric HIV neurocognitive measures and average values for those regions.

Statistical analyses. The Statistical Package for the Social Sciences (SPSS, V 24.0, IBM, Chicago, IL) was used to examine demographic and clinical parameters. Independent samples t-tests were performed to examine age, and gender differences between PHIV-infected and healthy control groups. Pearson’s correlation was performed to examine the association between cognitive measures and functional connections in the PHIV-infected youth group. The significance level was set at p = 0.05.
We used Pearson’s correlation to inter-correlate each of the clinical parameters—scan CD4%, log viral load, along with their psychological performance metrics (IQ Neurocognitive score, Speed of Processing, Attention/Vigilance, Working Memory, Verbal Learning, Visual Learning, Reasoning and Problem Solving, Social Cognition, Overall Composite IQ score, Executive Functioning, Visual Perceptual Delayed Recall, Psychomotor Functions, Abstract Thinking), Maternal Substance Use, School Difficulties, and whether or not the PHIV had a diagnosis of HIV Encephalopathy. The significance level was set at \( p < 0.05 \). In order to avoid multicollinearity, we reported and removed from further analysis several psychological variables that were inter-correlated.

We used the SPM12 software package for ANCOVA analyses of control (n = 16) and PHIV (n = 11) groups with age and sex as co-variates. Traditional neuroimaging findings are reported as t-statistic, where a t statistic is calculated at each voxel location. Groups of adjacent voxels identified as significant are termed clusters. Clusters of rs-fMRI differences are overlaid on anatomical backgrounds for visualization. Correction for multiple comparisons was performed with cluster thresholding, which consists of two stages. After thresholding with an uncorrected threshold of \( p < 0.001 \) and minimum cluster size of 3, clusters are each thresholded based on family-wise error (FWE) correction at \( p < 0.05 \).

For the regions that showed significant differences in ALFF and ReHo between PHIV and healthy controls, we used intrinsic masking in SPM to correlate the ALFF and ReHo data in the 11 pediatric HIV patients with the clinical parameters of viral load, CD4 and neuropsychological variables. The significance level of contrasts was set to \( p < 0.001 \) with cluster size greater than or equal to 3.

**Table 2** depicts the brain regions showing higher ALFF and ReHo in PHIV compared to controls. We found predominantly in the bilateral cerebral white matter an increased spontaneous regional neuronal activity in PHIV compared to healthy controls. There were no brain regions that showed significantly lower ALFF or ReHo in PHIV compared to control. We did not obtain a significant difference in fALFF between the patients and controls.

Table 3 shows positive (\( p < 0.01 \), cluster size \( \geq 3 \)) associations of \( \log_{10} \) viral load with ALFF and ReHo for the 11 patients in regions of PHIV-Control differences (Table 1).

Table 4 shows negative (\( p < 0.01 \), cluster size \( \geq 3 \)) associations of Social Cognition, Psychomotor Functioning and Abstract Thinking with ALFF at the left cerebral white matter in the left medial orbital gyrus and with the ReHo at the right cerebral white matter in the 11 PHIV patients in regions of PHIV-Control differences (Table 1). Table 4 also lists the only significantly positive (\( p < 0.01 \), cluster size \( \geq 3 \)) association of Social Cognition with ReHo, which appeared in the right central operculum/right cerebral white matter.
Discussion

Youth perinatally infected with HIV showed altered resting state activity, reflecting differences in brain function relative to healthy counterparts. Specifically, we found higher activity of low frequency oscillations (ALFF) in PHIV youth compared to controls, especially in the cerebral matter of prefrontal cortex where it could indicate higher sympathetic activity. Per the original study by Biswal and colleagues, ALFF in a resting state reflects correlations between blood flow and oxygenation, which is interpreted as brain regions being functionally related\(^40\).

Previous studies on acute traumatic brain injury reported higher ALFF and increased spontaneous activity in low frequency bands (0.01–0.08 Hz)\(^82\). We found a group of voxels in cerebral white matter in the medial orbital gyrus with higher ALFF together with a higher level of a marker of functional similarity, ReHo, in PHIV compared to controls. We did not observe a significant difference in the groups for in neural ALFF (f-ALFF); since this measure is considered gray matter specific\(^55\), the findings of altered ALFF likely reflect at least in part differences in non-neural physiology, including in the white matter; such fluctuations in the fMRI signal may reflect inflammation and glial activation in PHIV relative to the control group.

Global effects such as motion or cerebral blood flow changes are unlikely to have influenced the findings. Low-frequency fluctuations in white matter are reduced relative to grey matter by 60%\(^60\) and the significance of white matter spontaneous neuronal firing in resting fMRI data has not been reported previously for HIV adults or PHIV. We had removed physiological artifacts using DRIFTER toolbox\(^78\), and detrended the fMRI data with linear detrending tools (as in\(^40\)). Additionally, we found that some ReHo and ALFF differences occurred in

| Type of resting fMRI data | Brain regions | Cluster p (FWE-corr) | Cluster p (unc) | Number of cluster voxels | MNI coordinate (mm) x | MNI coordinate (mm) y | MNI coordinate (mm) z | Peak t | Figure |
|--------------------------|---------------|---------------------|----------------|--------------------------|----------------------|----------------------|----------------------|-------|--------|
| ALFF                     | Right cerebral white matter/right medial prefrontal cortex | 0.000 | 0.000 | 338 | 18 | 42 | −16 | 6.16 | Figure 1A |
|                          | Left cerebral white matter/left prefrontal cortex | 0.002 | 0.00 | 199 | −8 | 56 | 8 | 5.64 | Figure 1B |
|                          | Left cerebral white matter | 0.120 | 0.004 | 83 | −12 | 38 | −6 | 5.16 | Figure 1C |
|                          | Left cerebral white matter | 0.260 | 0.010 | 64 | −34 | 36 | 10 | 4.80 | Figure 1D |
| ReHo                     | Right cerebral white matter | 0.0005 | 0 | 264 | 16 | 34 | −16 | 6.11 | Figure 2A |
|                          | Left cerebral white matter | 0.8613 | 0.0411 | 39 | −12 | 38 | −6 | 5.36 | Figure 2B |

Table 2. Resting fMRI data summary. Brain regions with cluster FWE-corrected p < 0.001 showing significantly higher regional neuronal activity (ALFF and ReHo) in patients with perinatally afflicted HIV (n = 11).
overlapping brain regions (cerebral white matter in the medial orbital gyrus). Thus, the findings of white matter differences in fMRI activity are unlikely to have been influenced by global effects.

Higher ALFF in particular could be related to underlying glial cycling or mitosis of glial cells. Microgliosis and neuroinflammation are long-term consequences of traumatic brain injury and pathogenesis in general83 and in PHIV we expect to find both microgliosis and neuroinflammation. HIV causes inflammation throughout the brain, which can persist despite control of the HIV virus in the peripheral blood84. The monocytes and T cells in the brain that are infected with HIV and have successfully crossed the blood–brain barrier can induce endothelial cells to release cytokines, consequently causing inflammation within the brain. In PHIV, this inflammation in the CNS may persist due to the difficulty of common medications being able to cross the blood–brain barrier into the CNS. The HIV-infected monocytes and T cells not only contaminate brain cells, but also release pro-inflammatory cytokines, viral proteins, and excitotoxins that can activate microglia, perivascular macrophages and astrocyte cells in the CNS and are potential reservoirs for the virus85. These are the main contributors to neuroinflammation in HIV infection and these cells release neurotoxic factors such as excitatory amino acids in addition to inflammatory mediators86. An HIV-infected CNS results in the increased activation of monocytes

Table 3. Correlation of resting fMRI data with viral load. Brain regions masked with significantly higher regional neuronal activity in the pediatric HIV patients compared to healthy controls, showed positive correlation (peak uncorrected $p < 0.01$, cluster size $\geq 3$) of $\log_{10}$ viral load with regional neuronal activity in the 11 pediatric HIV patients. +ve indicate positive correlation and −ve indicate negative correlation.

| NP domains            | Type of resting fMRI data | Brain regions                                    | Peak $p$ (uncorr) | Number of cluster voxels | MNI coordinate (mm) x | MNI coordinate (mm) y | MNI coordinate (mm) z | Peak $t$ | Figure |
|-----------------------|--------------------------|--------------------------------------------------|-------------------|--------------------------|-----------------------|-----------------------|-----------------------|---------|--------|
| Social cognition      | ALFF                     | Left cerebral white matter/left medial orbital gyrus | 0.000 (−ve)       | 3                        | 22                    | 48                    | − 18                  | 6.02    | Figure 1B |
|                       | ALFF                     | Left cerebral white matter                       | 0.001 (−ve)       | 3                        | − 50                  | 4                     | − 12                  | 4.26    | Figure 1B |
|                       | ALFF                     | Left cerebral white matter                       | 0.002 (−ve)       | 7                        | − 32                  | 36                    | 20                    | 3.84    | Figure 1B |
| ReHo                  | Right cerebral white matter | 0.000 (−ve)                                  | 5                  | 12                       | 28                    | − 10                  | 5.41                  | Figure 2A |
| Psychomotor functions | ALFF                     | Right cerebral white matter/right medial orbital gyrus | 0.002 (−ve)       | 4                        | 48                    | 0                     | − 4                   | 3.71    | Figure 2A |
| Abstract thinking     | ALFF                     | Right cerebral white matter                      | 0.001 (−ve)       | 3                        | 14                    | 56                    | − 16                  | 4.77    | Figure 1A |
|                       | ReHo                     | Right cerebral white matter                      | 0.006 (−ve)       | 5                        | 18                    | 44                    | − 12                  | 3.18    | Figure 2A |

Table 4. Correlation of resting fMRI data with neurocognitive variables. Brain regions masked with significantly higher regional neuronal activity in the pediatric HIV group compared to healthy controls, showed mostly negative correlation (peak uncorrected $p < 0.01$, cluster size $\geq 3$) of Social Cognition, negative correlation of Psychomotor Functioning and negative correlation of Abstract Thinking with regional neuronal activity in the 11 pediatric HIV patients. +ve indicate positive correlation and −ve indicate negative correlation.
and macrophage, resulting in astrocytosis and microglial activation. Glial cycling could also result from such pathophysiology, which could explain why we find higher ALFF activity in PHIV.

Our earlier finding of compromised white matter integrity found via Diffusion Tensor Imaging (DTI) in PHIV suggests structural differences may co-occur with the functional alterations, and inflammation is one possible cause of changes in both structure as seen with DTI and ALFF as seen here.

Recent research in adult HIV patients receiving cART vs healthy controls has found rs-fMRI differences mostly in ALFF measure. In these studies, various regions showed increased or decreased magnitude of ALFF which differs from the findings in our study. While there may be systematic differences between our PHIV group and other HIV populations, our small number of subjects precludes making strong generalizations.

The fact that we found higher ALFF in the cerebral white matter of orbital and frontal gyri in PHIV patients at the brain regions correlated with cognitive and emotional response could be indicative of ongoing neuroinflammatory insults. Similar to our present study, studies of leukoaraiosis (LA) have found a higher ALFF in cerebral white matter of superior orbital frontal gyri in the periventricular and subcortical areas of the brain. Moreover, LA patients also show cognitive impairment as found in our present study in the PHIV patients, suggesting there may be similar cognitive impairment and associated higher white matter ALFF activity and neuroinflammation in PHIV. Our findings are consistent with a previous study on postmortem brain tissue from patients with HIV-associated neurocognitive disorders, which showed signs of neuroinflammation. It has been reported that some antiretroviral medications used to treat HIV can contribute to the likelihood of neurocognitive disorders. Although new cART drugs are less toxic with fewer metabolic complications, chronic inflammation and other factors such as the irreparable damage of metabolic tissues suffered prior to the introduction of cART, side effects associated with other medications, and host genetic risk can still contribute to the neurocognitive impairment observed in PHIV-infected youth and in general HIV-infected patients.

Limitations of our study include the relatively small sample size, so further studies with larger cohorts are needed to confirm our findings. In addition, the cross-sectional design limited our ability to assess the impact of HIV on brain development over time. Future rs-fMRI study on PHIV youth should also include perinatally HIV-exposed uninfected youth apart from the HIV-unexposed healthy controls group for better distinguishing potential mechanisms.

Conclusions

The findings are consistent with the hypothesis that long-term higher neuroinflammation and associated neurorepair in perinatally HIV-infected patients may be reflected in the higher regional spontaneous activity that we observe in the white matter in PHIV patients compared to healthy controls. Moreover, the higher cerebral white matter spontaneous activity correlated with higher viral load and decreased cognition, suggesting a role for neuroinflammation in impaired cognition. Resting state fMRI, particularly ALFF data that has been utilized to interpret neuroinflammation in this study, shows promise as a future tool to follow the effects of HIV on brain function, which is an important measure since these PHIV youth survive many years into adulthood. Such noninvasive measures may detect subtle ongoing inflammation, which could potentially be targeted with anti-inflammatory therapy or changes in antiretroviral treatment to preserve brain health in these surviving patients. In future, larger sample size studies should consider other neuroimaging techniques to confirm inflammation in the white matter in PHIV.

Received: 15 January 2020; Accepted: 12 January 2021
Published online: 04 February 2021

References

1. Palella, F. J. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853–860. https://doi.org/10.1056/NEJM199803263381301 (1998).
2. Brady, M. T. et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J. Acquir. Immune Defic. Syndr. 53, 86–94. https://doi.org/10.1097/QAI.0b013e3181b9869f (2010).
3. Gona, P. et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 296, 292–300. https://doi.org/10.1001/jama.296.3.292 (2006).
4. Haiza, R., Siberry, G. K. & Mofenson, L. M. Growing up with HIV: Children, adolescents, and young adults with perinatally acquired HIV infection. Annu. Rev. Med. 61, 169–185. https://doi.org/10.1146/annurev.med.051008.151127 (2010).
5. Lee, G. M. et al. Quality of life of children and adolescents: Impact of HIV infection and antiretroviral treatment. Pediatrics 117, 273–283. https://doi.org/10.1542/peds.2005-0323 (2006).
6. Letendre, S. et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65, 63–70. https://doi.org/10.1001/archneurol.2007.31 (2008).
7. Patel, K. et al. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS 23, 1893–1901. https://doi.org/10.1097/QAD.0b013e32832cd041 (2009).
8. Varatharajan, L. & Thomas, S. A. The transport of anti-HIV drugs across blood-CNS interfaces: Summary of current knowledge and recommendations for further research. Antivir. Res. 82, A99–A109. https://doi.org/10.1016/j.antiviral.2008.12.013 (2009).
9. Marra, C. M. et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23, 1359–1366. https://doi.org/10.1097/QAD.0b013e32832c4152 (2009).
10. Robertson, K., Linner, J. & Meeker, R. B. Antiretroviral neurotoxicity. J. Neurovirol. 18, 388–399. https://doi.org/10.1007/s1336 5-012-0120-3 (2012).
11. Vigano, A. et al. Tenovir disoproxil fumarate and bone mineral density: A 60-month longitudinal study in a cohort of HIV-infected youths. Antivir. Ther. 15, 1053–1058. https://doi.org/10.3851/IJTP1630 (2010).
12. Laughton, B., Cornell, M., Boivin, M. & Van Rie, A. Neurodevelopment in perinatally HIV-infected children: A concern for adolescence. J. Int. AIDS Soc. https://doi.org/10.7448/ias.16.1.18603 (2013).
13. Martin, S. C. et al. Cognitive functioning in school-aged children with vertically acquired HIV infection being treated with highly active antiretroviral therapy (HAART). Dev. Neuropsychol. 30, 633–657. https://doi.org/10.1080/15526942.2002.1_ (2006).
14. Smith, R. et al. Effects of perinatal HIV infection and associated risk factors on cognitive development among young children. Pediatrics 117, 851–862. https://doi.org/10.1542/peds.2005-0086 (2006).

15. van Arnhem, L. A. et al. Neurologic abnormalities in HIV-1 infected children in the era of combination antiretroviral therapy. PLoS ONE 8(10), e764398. https://doi.org/10.1371/journal.pone.0064398 (2013).

16. Van Rie, A., Dow, A., Mupuala, A. & Stewart, P. Neuromodulatory trajectory of HIV-infected children accessing care in Kinshasa, Democratic Republic of Congo. J. Acquir. Immune. Defic. Syndr. 52, 636–642. https://doi.org/10.1097/QAI.0b013e3181b264e6 (2009).

17. Whitehead, N., Potterton, J. & Coovadia, A. The neurodevelopment of HIV-infected children on HAART compared to HIV-exposed but uninfected infants. AIDS Care 26, 497–504. https://doi.org/10.1080/095401213.2013.841828 (2014).

18. Govender, R., Eley, B., Walker, K., Petersen, R. & Wilmhurst, J. M. Neurologic and neurobehavioral sequelae in children with human immunodeficiency virus (HIV-1) Infection. J. Child Neurol. 26, 1355–1364. https://doi.org/10.1089/0883073811405203 (2011).

19. Musielak, K. A. & Fine, J. G. An updated systematic review of neuroimaging studies of children and adolescents with perinatally acquired HIV. J. Pediatr. Neuropsychol. 11, 1–9. https://doi.org/10.1016/j.pjnp.2006.10.006 (2007).

20. Nagarajan, R. et al. Neuropsychological function and cerebral metabolites in HIV-infected youth. J. Neuroimmune Pharm. 7, 981–990. https://doi.org/10.1016/j.jnipharm.2011.04.012 (2012).

21. Ackermann, C. et al. White matter signal abnormalities in children with suspected HIV-related neurologic disease on early combination antiretroviral therapy. Pediatr. Infect. Dis. J. 33, E207–E212. https://doi.org/10.1097/INF.0b013e3182000084 (2014).

22. Donald, K. A. et al. HIV encephalopathy: Pediatric case series description and insights from the clinical coalface. Aids Res. Ther. 12, 92. https://doi.org/10.1186/s12984-015-0042-7 (2015).

23. Hoare, J. et al. A diffusion tensor imaging and neurocognitive study of HIV-positive children who are HAART-naive “slow progressors”. J. Neurovirol. 18, 205–212. https://doi.org/10.1016/j.jnvr.2011.01.004 (2012).

24. Hoare, J. et al. Systematic review of neuroimaging studies in vertically transmitted HIV positive children and adolescents. Metab. Brain Dis. 29, 221–229. https://doi.org/10.1007/s11012-013-9456-5 (2014).

25. Sarma, M. K. et al. Regional brain grey and white matter changes in perinatally HIV-infected adolescents. Neuroimage Clin. 4, 29–34. https://doi.org/10.1016/j.nicl.2013.10.012 (2014).

26. Uban, K. A. et al. White matter microstructure among youth with perinatally acquired HIV is associated with disease severity. Aids 29, 1035–1044. https://doi.org/10.1097/QAD.0b013e3283306e60 (2015).

27. Cohen, S. et al. Cerebral injury in perinatally HIV-infected children compared to matched healthy controls. Neurology 86, 19–27. https://doi.org/10.1212/WNL.0000000000002209 (2016).

28. Lewis-de los Angeles, C. P. et al. Deformed subcortical structures are related to past HIV disease severity in youth with perinatally acquired HIV infection. J. Pediatr. Infect. Dis. Soc. 5, 56–514. https://doi.org/10.1016/j.pid.2014.02.001 (2016).

29. Izbudak, I. et al. Perinatally HIV-infected youth presenting with acute stroke: Progression/evolution of ischemic disease on neuroimaging. J. Neuroradiol. 40, 172–180. https://doi.org/10.1016/j.neurad.2012.08.001 (2013).

30. Lewis-de los Angeles, C. P. et al. Lower total and regional grey matter brain volumes in youth with perinatally-acquired HIV infection: Associations with HIV disease severity, substance use, and cognition. Brain Behav. Immun. 62, 100–109. https://doi.org/10.1016/j.bbi.2017.01.004 (2017).

31. Yavad, S. K. et al. Altered structural brain changes and neurocognitive performance in pediatric HIV. Neuroimage-Clin 14, 316–322. https://doi.org/10.1016/j.nicl.2017.01.032 (2017).

32. Andronikou, S. et al. Correlating brain volume and callosal thickness with clinical and laboratory indicators of disease severity in children with HIV-related brain disease. Child. Neurol. Syn. 30, 1549–1557. https://doi.org/10.1038/s41381-014-2343-3 (2014).

33. Hoare, J. et al. Clinical associations of white matter damage in cART-treated HIV-positive children in South Africa. J. Neurovirol. 21, 120–128. https://doi.org/10.1177/1078627315610203 (2015).

34. Biswal, B., Yetkin, F. Z., Haughton, V. M. & Hyde, J. S. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn. Reson. Med. 34, 537–541 (1995).

35. Supok, K. et al. Development of functional and structural connectivity within the default mode network in young children. Neuroimage 52, 290–301. https://doi.org/10.1016/j.neuroimage.2010.04.009 (2010).

36. Thomason, M. E. et al. Resting-state fMRI can reliably map neural networks in children. Neuroimage 55, 165–175. https://doi.org/10.1016/j.neuroimage.2010.11.080 (2011).

37. Anderson, J. S. et al. Functional connectivity magnetic resonance imaging classification of autism. Brain 134, 3739–3751. https://doi.org/10.1093/brain/awv263 (2011).

38. Bassett, D. S., Nelson, B. G., Mueller, B. A., Camchong, J. & Lim, K. O. Altered resting state complexity in schizophrenia. Neuroimage 59, 2196–2207. https://doi.org/10.1016/j.neuroimage.2011.10.002 (2012).

39. Chen, G. et al. Classification of Alzheimer disease, mild cognitive impairment, and normal cognitive status with large-scale network analysis based on resting-state functional MR imaging. Radiology 259, 213–221. https://doi.org/10.1148/radiol.10100734 (2011).

40. Craddock, R. C., Holzheiser, P. E., Hu, X. P. P. & Mayberg, H. S. Disease state prediction from resting state functional connectivity. Magn. Reson. Med. 62, 1619–1628. https://doi.org/10.1002/mrm.22159 (2009).

41. Doria, V. et al. Emergence of resting state networks in the preterm human brain. Proc. Natl. Acad. Sci. USA 107, 2005–2020. https://doi.org/10.1073/pnas.1007921107 (2010).

42. Koch, W. et al. Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer’s disease. Neurobiol. Aging 33, 466–478. https://doi.org/10.1016/j.neurobiolaging.2010.04.013 (2012).

43. Shimony, J. S. et al. Resting-state spontaneous fluctuations in brain activity: A new paradigm for presurgical planning using fMRI. Acad. Radiol. 16, 578–583. https://doi.org/10.1016/j.acra.2009.02.001 (2009).

44. Smyser, C. D. et al. Longitudinal analysis of neural network development in preterm infants. Cereb. Cortex 20, 2852–2862. https://doi.org/10.1093/cercor/bhq035 (2010).

45. Zhang, D. Y. et al. Preoperative sensorimotor mapping in brain tumor patients using spontaneous fluctuations in neuronal activity imaging with functional magnetic resonance imaging: Initial experience. Neurosurgery 65, 226–236. https://doi.org/10.1093/neuros/nyv088 (2009).
93. Bramlett, H. M. & Dietrich, W. D. Long-term consequences of traumatic brain injury: Current status of potential mechanisms of injury and neurological outcomes. *J. Neurotrauma* **32**, 1834–1848. https://doi.org/10.1089/neu.2014.3352 (2015).
94. Phillips, N. *et al.* HIV-associated cognitive impairment in perinatally infected children: A meta-analysis. *Pediatrics* https://doi.org/10.1542/peds.2016-0893 (2016).
95. Brinkman, T. M. *et al.* Cerebral white matter integrity and executive function in adult survivors of childhood medulloblastoma. *Neuro-Oncology* **14**, 25–36. https://doi.org/10.1093/neuonc/noq214 (2012).
96. Kumar, A. & Loane, D. J. Neuroinflammation after traumatic brain injury: Opportunities for therapeutic intervention. *Brain Behav. Immun.* **26**, 1191–1201. https://doi.org/10.1016/j.bbi.2012.06.008 (2012).

**Acknowledgements**
This research was supported by a research grant from the National Institute of Neurological Disorders and Stroke (NINDS) NS090956. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We also acknowledge the scientific support of Dr. Irwin Walot.

**Author contributions**
M.K.S., M.A.K., B.B., and M.A.T. contributed to the design of experiments; M.K.S., M.A.K., T.W., J.V. and M.A.T. collected the data; M.K.S., A.P., P.M.M., and B.B. analyzed the data; D.E.M., K.N.S., J.D., A.K., E.O., J.A.C. contributed to patient-related aspects; M.K.S., M.A.K., P.M.M., A.P., and M.A.T. contributed to the data interpretation. All authors contributed to writing the manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**
**Correspondence** and requests for materials should be addressed to M.A.T.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021